Disc Medicine, Inc. (NASDAQ:IRON)
| Market Cap | $3.20B-4.4% |
| Revenue (ttm) | $0 |
| Net Income | -$243.10M-34.2% |
| EPS | -$6.36-18.9% |
| Shares Out | 38.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 761,213 |
| Open | $86.16 |
| Previous Close | $87.08 |
| Day's Range | $82.66 - $87.14 |
| 52-Week Range | $40.00 - $99.50 |
| Beta | 2.01 |
| Analysts | Buy |
| Price Target | $127.14(+52.76%) |
| Earnings Date | Feb 25, 2027 |
About IRON
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
7 firms rating IRON in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$IRON stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IRON holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IRON's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IRON Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IRON patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IRON from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IRON
| IWMiShares Russell 2000 ETF | $73.97M |
| XBIState Street SPDR S&P Biotech ETF | $66.20M |
| VTIVanguard Morningstar Total Stock Market ETF | $64.09M |
| IWOiShares Russell 2000 Growth ETF | $26.94M |
| VXFVanguard Extended Market ETF | $24.47M |
| DFASDimensional - US Small Cap ETF | $20.29M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from IRON’s recent data — informational, not investment advice
What’s Behind the Score
News check: Guggenheim initiation at Buy with $132 PT and ASH presentation announcements offset mixed Q3 results sentiment.
Recent Insider Activity
Insider Score Trend Over Time
-35.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 2.09% |
| TDNA | T. Rowe Price Biotech ETF | 1.48% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.95% |
| JDOC | JPMorgan Healthcare Leaders ETF | 0.77% |
| XBI | State Street SPDR S&P Biotech ETF | 0.61% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.53% |
| SCDS | JPMorgan Fundamental Data Science Small Core ETF | 0.40% |
| ESUM | Eventide US Market ETF | 0.40% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.21% |
| IWO | iShares Russell 2000 Growth ETF | 0.19% |
| TMSL | T. Rowe Price Small-Mid Cap ETF | 0.18% |
| IBB | iShares Biotechnology ETF | 0.17% |
Weight is the stock’s share of each fund’s holdings.